Open AccessDose to organ at risk and dose prescription in liver SBRT
Author(s) -
M. Rives,
F. Izar,
L. Parent,
Anouchka Modesto,
Portier Guillaume,
Sylvain Kirzin
Publication year - 2017
Publication title -
reports of practical oncology and radiotherapy
Language(s) - English
Resource type - Journals
eISSN - 2083-4640
pISSN - 1507-1367
DOI - 10.1016/j.rpor.2017.03.001
Subject(s) - medicine , radiosurgery , radiology , metastasis , duodenum , biliary tract , radiation therapy , cancer
Stereotactic body radiation therapy (SBRT) is delivered in a curative intent to many primary and secondary tumors. Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An excellent local control is obtained with doses from 20 to 60 Gy. For primary hepatic tumors, results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology must be taken into account. Radiation induced liver disease (RILD) is not frequent in its classical presentation, but modifications of liver enzymes are often observed. Other toxicities of SBRT on the duodenum, small bowel and biliary tract are also described. With respect to contraindications and dose limitations on surrounding structures, SBRT is well tolerated and takes place among curative treatment of liver tumors, as surgery, radiofrequency and embolization.